title: Parkinson's disease: in vivo assessment of disease progression using positron emission tomography.
abstract: Over the past two decades, positron emission tomography (PET) has provided valuable insights into the mechanisms of nigrostriatal degeneration in Parkinson's disease (PD). Furthermore, it allows the in vivo assessment of disease progression and the evaluation of treatment interventions. In this review, we shall discuss some of the issues and concerns that arise with the use of PET as a surrogate marker of disease progression in Parkinson's disease.
authors.affiliation: Pacific Parkinson's Research Centre, University of British Columbia, Vancouver Hospital and Health Sciences Centre, Purdy Pavilion, 2221 Wesbrook Mall, Vancouver, BC, Canada V6T 2B5.
authors.forename: Wing Lok
authors.initials: WL
authors.lastname: Au
authors.forename: John R
authors.initials: JR
authors.lastname: Adams
authors.forename: André R
authors.initials: AR
authors.lastname: Troiano
authors.forename: A Jon
authors.initials: AJ
authors.lastname: Stoessl
mesh_terms: D000818:Animals; D001921:Brain / Q000000981:diagnostic imaging*; D018450:Disease Progression; D004298:Dopamine; D050483:Dopamine Plasma Membrane Transport Proteins; D006801:Humans; D008562:Membrane Glycoproteins; D026901:Membrane Transport Proteins; D008959:Models, Neurological; D009419:Nerve Tissue Proteins; D010300:Parkinson Disease / Q000000981:diagnostic imaging*; D049268:Positron-Emission Tomography; D050492:Vesicular Biogenic Amine Transport Proteins
chemical_list: D050483:Dopamine Plasma Membrane Transport Proteins; D008562:Membrane Glycoproteins; D026901:Membrane Transport Proteins; D009419:Nerve Tissue Proteins; D050492:Vesicular Biogenic Amine Transport Proteins; D004298:Dopamine